Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?
- PMID: 35429038
- DOI: 10.1111/apt.16909
Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?
Comment on
-
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.Aliment Pharmacol Ther. 2022 May;55(10):1311-1319. doi: 10.1111/apt.16816. Epub 2022 Feb 15. Aliment Pharmacol Ther. 2022. PMID: 35166374 Free PMC article.
References
REFERENCES
-
- Goodoory VC, Ng CE, Black CJ, Ford AC. Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2022; https://doi.org/10.1111/apt.16816
-
- Lisi DM. Lotronex withdrawal. Arch Intern Med. 2002;162:101.
-
- Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745-67.
-
- Lucak SL. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol. 2010;3:165-72.
-
- Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A, et al. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci. 2014;344:80-7.